ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

ClinicalTrials.gov ID: NCT03634007

Public ClinicalTrials.gov record NCT03634007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease

Study identification

NCT ID
NCT03634007
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Lexeo Therapeutics
Industry
Enrollment
15 participants

Conditions and interventions

Interventions

  • LX1001 Biological

Biological

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 5, 2019
Primary completion
Nov 6, 2024
Completion
Nov 6, 2024
Last update posted
Oct 19, 2025

2019 – 2024

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
4
Facility City State ZIP Site status
K2 Medical Research Maitland Florida 32751
PPD- Orlando Research Unit Orlando Florida 32806
Weill Cornell Medicine New York New York 10021
Duke University Durham North Carolina 27708

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03634007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03634007 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →